UGT1A1Your two copies: *1/*28+*60+*80
Intermediate metabolizer
One copy works and one works less well.
Clears bilirubin and some drugs, such as the cancer drug irinotecan.
This result doesn't change the label.
Example report. Made from Leslie Knope's DNA data so you can see what yours will look like. Get your own report
Oncology · ChemotherapiesExample report
Sacituzumab Govitecan-Hziy
Trodelvy
Use as directed
Your body processes this drug a bit slower than average. The FDA gives no dose change for your result, so the usual dose is used.
The genes behind this label
The guidelines read one gene for sacituzumab govitecan-hziy. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
UGT1A1Intermediate metabolizer
- In plain words
- Your body processes this drug a bit slower than average. The FDA gives no dose change for your result, so the usual dose is used.
- What it means
- No FDA guidance for this phenotype
- What the label suggests
- Initiate therapy with recommended starting dose.
About sacituzumab govitecan-hziy
Sacituzumab govitecan-hziy (Trodelvy) is an antibody-drug conjugate for advanced breast cancer: an antibody that seeks out the Trop-2 protein on cancer cells, carrying SN-38, the active form of the chemotherapy drug irinotecan.
- Used for
- Locally advanced or metastatic triple-negative breast cancer, and HR-positive, HER2-negative breast cancer after earlier treatments
Others in oncology
Compare all 13 oncology- BelinostatBeleodaq Use as directed
- BelzutifanWelireg Use as directed
- CapecitabineXeloda, Xitabin, Kapetral Use as directed
- ErdafitinibBalversa Use as directed
- FluorouracilAdrucil, Carac Use as directed
- GefitinibIressa Use with caution
- IrinotecanCamptosar, Onivyde Use as directed
- MercaptopurinePurinethol Use as directed
Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.